ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

Retinitis Pigmentosa Market Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.

Retinitis pigmentosa is an inherited degenerative disorder which affects retina’s ability to respond to light. It results in progressive loss of vision, eventually leading to blindness.

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

This work can be read in the journal PLOS Biology. Retinitis pigmentosa is the most common hereditary retinal disease in humans, with a prevalence of one in every 4,000 people worldwide.

Retinitis pigmentosa is an eye disease in which there is damage to the retina. Approximately 2 million individuals (about 1 in 4,000) worldwide are affected by the condition, which typically ...

Treatment With 9-cis Beta-Carotene-Rich Powder in Patients With Retinitis Pigmentosa: A Randomized Crossover Trial Rotenstreich Y, Belkin M, Sadetzki S, et al. JAMA Ophthalmol. 2013;131:985-992.